Patients with non-small cell lung cancer and poor performance status: A significant population with limited data

Seminars in Oncology

Volumn 31, Issue SUPPL. 11, 2004, Pages 1-2

  Langer, Corey ^a   Lilenbaum, Rogerio ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b Miami Beach FL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE;

CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; COMORBIDITY; DRUG DELIVERY SYSTEM; HUMAN; LUNG NON SMALL CELL CANCER; MORTALITY; PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; SURVIVAL RATE;

EID: 10044257861     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.10.001     Document Type: Editorial

References (15)

1. American Cancer Society Cancer Facts and Figures 2004 2004 American Cancer Society Atlanta, GA
2. C.J. Langer Dilemmas in management The role of chemotherapy in PS2 advanced NSCLC and the potential role of CT-2103 (Xyotax) Oncologist 9 2004 398 405
3. C.J. Sweeney, J. Zhu, A.B. Sandler Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594 A phase II trial in patients with metastatic nonsmall cell lung carcinoma Cancer 92 2001 2639 2647
4. G. Buccheri, D. Ferrigno, M. Tamburini Karnofsky and ECOG performance status scoring in lung cancer A prospective, longitudinal study of 536 patients from a single institution Eur J Cancer 32A 1996 1135 1141
5. D.G. Pfister, D.H. Johnson, C.G. Azzoli American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline Update 2003 J Clin Oncol 22 2003 330 353
6. R.C. Lilenbaum, J. Herndon, M. List Single-agent versus combination chemotherapy in advanced non-small cell lung cancer (NSCLC) A CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness Proc Am Soc Clin Oncol 21 2002 1a (abstr 2)
7. A. Jemal, L.X. Clegg, E. Ward Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival Cancer 101 2004 3 27
8. N.K. Aaronson, S. Ahmedzai, B. Bergman The European Organization for Research and Treatment of Cancer QLQ-C30 A quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
9. D.F. Cella The Functional Assessment of Cancer Therapy-Lung and Lung Cancer Subscale assess quality of life and meaningful symptom improvement in lung cancer Semin Oncol 31 suppl 9 2004 11 15
10. H. Spiridonidis, M. Tao, L. Laufman Symptomatic response to a non-platinum doublet in performance status 2 (PS 2) patients with non-small cell lung cancer Proc Am Soc Clin Oncol 23 2004 688 (abstr 7303)
11. J. Latreille, V. Hirsh, H. Kresiisman Sequential therapy with vinorelbine followed by gemcitabine in patients with metastatic non-small cell lung cancer, performance status 2 or elderly with comorbidities A multicenter phase II trial Proc Am Soc Clin Oncol 23 2004 643 (abstr 7119)
12. D.S. Ettinger Is there a preferred combination chemotherapy regimen for metastatic non-small cell lung cancer? Oncologist 7 2002 226 233
13. C. Gridelli, P. Maione, V. Castaldo Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer Br J Cancer 89 2003 1827 1829
14. N. Hanna, F.A. Shepherd, F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
15. D.M. Bodkin, M. Neubauer, M.G. Bolton Phase 2 study of first line chemotherapy using CT-2103 (XYOTAX) in patients with non-small-cell lung cancer who are >69 years of age or who have performance status (PS) = 2 Eur J Cancer 1 2003 S242 (abstr 806)